viernes, 19 de abril de 2024

Moving the conversation about obesity beyond the scale By Jonathan IsaacsohnApril 19, 2024 Ozempic and other semaglutide drugs have revolutionized obesity in more ways than one. Not only do the drugs provide an effective treatment for weight loss — alongside improving cardiovascular health and easing sleep apnea — but they have helped change the social perception of obesity from a lifestyle choice to a disease. That’s something clinicians have long advocated for; the National Institutes of Health identified obesity as a disease in 1998. STAT’s Matt Herper and Elaine Chen described the potential cultural impact of these drugs in a prescient piece back in March 2023. And in a new First Opinion, Jonathan Isaacsohn, a cardiologist and CEO of CinRx Pharma, writes that this reframing of obesity helps drug developers because it validates and supports their work. The spotlight on GLP-1 drugs is also fueling interest in what scientists see as the next frontier in this line of research: weight loss drugs that do not reduce lean mass. Read more.

No hay comentarios: